Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients...

Keywords

IpilimumabMedicineProstate cancerInternal medicineOncologyCancerImmunotherapyAdverse effect

Affiliated Institutions

Related Publications

The biologic importance of tumor‐infiltrating lymphocytes

F. Stephen Hodi , Glenn Dranoff

Detailed pathologic analysis has delineated a close association between intratumoral CD 8 + cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the...

2010 Journal of Cutaneous Pathology 55 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

Peter Schmid , Sylvia Adams , Hope S. Rugo +15 more

Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and t...

2018 New England Journal of Medicine 4116 citations

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

Julie R. Brahmer , Christina Lacchetti , Bryan J. Schneider +26 more

Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint i...

2018 Journal of Clinical Oncology 3484 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Publication Info

Year: 2012
Type: article
Volume: 13
Issue: 5
Pages: 509-517
Citations: 355
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

355

OpenAlex

Cite This

APA Style

                            
                                
                                    Alfons JM van den Eertwegh, 
                                
                                    Jurjen Versluis, 
                                
                                    H. Pieter van den Berg
                                
                                et al.
                            
                            (2012). 
                            Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. 
                            The Lancet Oncology
                            , 13
                            (5)
                            , 509-517.
                            https://doi.org/10.1016/s1470-2045(12)70007-4
                        

Identifiers

DOI: 10.1016/s1470-2045(12)70007-4